Benefits of Combining MCT With CR in the Recovery of Patients With Psychotic Spectrum Disorders

Launched by UNIVERSITAT AUTONOMA DE BARCELONA · May 16, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating whether a combination of two therapies, called REHACOP and Metacognitive Training (MCT), can help people with certain mental health conditions, like schizophrenia and related disorders, recover better than MCT alone. The researchers want to find out if this combined therapy improves not just clinical recovery, which means feeling better from symptoms, but also personal and social recovery. They’ll be looking at how well individuals think and interact with others, and whether the effects of the treatment last over time.

To participate, individuals must meet specific criteria, such as being diagnosed with one of the targeted psychotic disorders and being stable enough not to have needed hospitalization in the last three months. Participants will attend either eight or twelve weekly therapy sessions, depending on which group they are in, and will complete some self-assessments to track their progress. This study is currently recruiting participants of all genders, aged between 18 and 65, who are willing to join and give informed consent.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Presence of one of the e following diagnostics according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5): schizophrenia, schizophreniform disorder, delusional disorder, brief psychotic disorder, schizoaffective disorder, and non specified schizophrenia spectrum disorder and other psychotic disorders.
• • Be in a stable clinical phase (without psychiatric hospitalization in the last 3 months).
• • Have good adherence to pharmacological treatment.
• • T-score \< 40 in any cognitive outcome measured by TAVEC, CPT-IP, TMT, Stroop, WSCT, FAS and WAIS (Vocabulary, Digit Forward, Digit Backwards and Digit Symbol Coding.
• • Willing to participate in the study expressed by providing signed informed consent.
• Exclusion Criteria:
• • Presence of traumatic brain lesion, dementia or intellectual discapacity (IQ \<70).
• • Positive and Negative Syndrome Scale (PANSS) score \>= 5 in hostility and lack of cooperation and \>= 6 in suspiciousness.
• • Presence of an additional diagnosis of severe disorder related to substances.
• • Having participated in a CR and/or MCT intervention in the year prior to incorporation into the study.